The Animal Biology

Bìol. Tvarin. 2020; 22(1): 26–30.
https://doi.org/10.15407/animbiol22.01.026
Received 23.09.2019 ▪ Accepted 14.11.2019 ▪ Published online 01.05.2020

Hematological indices of rats after administration of enrofloxacin as a subunit of polymer

¹Odesa State Agrarian University
3a Krasnova str., Odesa, 65012, Ukraine

²Institute of Animal Biology NAAS,
38 V. Stus str., Lviv, 79034, Ukraine

³Lviv Polytechnic National University,
2 St. George sq., Lviv, 79013, Ukraine

⁴State Scientific and Research Control Institute of Veterinary Medicinal Products and Feed Additives,
11 Donetska str., Lviv, 79019, Ukraine

The influence of antibiotic enrofloxacin and PEG-400 polymer complex on hemoglobin content, red and white blood cell count, and blood leukogram state of apparently healthy rats has been studied. The enrofloxacin contains reactive carboxyl groups in the molecule structure, it makes possible to carry out modifications for obtaining new compounds. The complex of enrofloxacin with polymer was obtained by interaction of enrofloxacin hydrochloride with polyethylene glycol-400. There were not any abnormal changes in the physiological state of the animals after administration none of the tested substances. The effect of the enrofloxacin + PEG400 complex in 7 days after the injection was manifested by the decrease of red blood cells count and hemoglobin concentration in the rats’ blood, and after 14 and 21 days — by activation of hematopoietic function. Particularly, on the 14^th day red blood cell counts in the blood of control animals and animals treated with enrofloxacin+PEG-400 complex were approximately equal and ranged 4.6–4.7×10¹²/L, and were 8.0–16.4 % (P>0.05) lower than in experimental rats received the antibiotic and PEG-400 separately. At the same time, in the absence of significant difference in red blood cell count, the blood hemoglobin concentration increased. This concentration reached a maximum after the administration of the enrofloxacin + PEG-400 complex (132.2±4.10 g/L), but it became a little bit lower (2.7–8.9 g/L) in rats’ blood of other experimental groups. The effects of PEG-400 and enrofloxacin both separately and in complex of enrofloxacin + PEG400, were characterized by the decrease in leukocytes count throughout the experiment. So, after the 21^st day of experiment white blood cell count was the lowest in the blood of animals after the enrofloxacin + PEG-400 complex administration (4.2±0.41×10⁹/L; P<0.001) in comparison with the control group; but when the enrofloxacin and PEG-400 were administered separately, white blood cell count was 14.5 (P<0.05) and 34.8 % (P<0.01) lower, respectively. Changes in the ratio of different types of leukocytes in the blood of rats characterize the reaction of the body to the introduction of the test substances, the intensity of which decays on the 7^th day of the experiment.

Key words: rats, nanopolymers, antibiotic, enrofloxacin, hematological indices, WBC

1. Chekh BO, Dron IA, Vynnytska SI, Oleksa VV, Atamaniuk IE, Vlizlo VV. Antibacterial activity of complex of enrofloxacin with nanopolymer GluLa-DPG-PEG600. Bìol. Tvarin. 2017; 19(4): 83–87. DOI: 10.15407/animbiol19.04.083. (in Ukrainian)
2. Chekh BO, Ferens MV, Ostapiv DD, Samaryk VY, Varvarenko SM, Vlizlo VV. Characteristics of novel polymer based on pseudo-polyamino acids GluLa-DPG-PEG600: binding of albumin, biocompatibility, biodistribution and potential crossing the blood-brain barrier in rats. Ukr. Biochem. J. 2017; 89(4): 13–21. DOI: 10.15407/ubj89.04.013. (in Ukrainian)
3. Directive 2010/63/EU of the European Parliament and of the Council of September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union L276/33. 86/609/EC. 20.10.2010.
4. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature. 2008; 451: 990–993. DOI: 10.1038/nature06536.
5. Kirichek L.T. Antibiotics in modern chemotherapy. International Medical Journal. 2003; 1: 118–121.
6. Martinho N, Damgé C, Reis CP. Recent advances in drug delivery systems. J. Biomater. Nanobiotechnol. 2011; 2(5): 510–526. DOI: 10.4236/jbnb.2011.225062.
7. Mohanraj VJ, Chen Y. Nanoparticles — a review. Tropical J. Pharm. Res. 2006; 5(1): 561–573. DOI: 10.4314/tjpr.v5i1.14634.
8. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev. 2013; 65(13–14): 1803–1815. DOI: 10.1016/j.addr.2013.07.011.
9. Romberg B, Metselaar JM, Baranyi L, Snel CJ, Bünger R, Hennink WE, Szebeni J, Storm G. Poly(aminoacid)s: Promising enzymatically degradable stealth coatings for liposomes. Intern. J. Pharmaceut. 2007; 331(2): 186–189. DOI: 10.1016/j.ijpharm.2006.11.018.
10. Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, Swai HS. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine. 2010; 6(5): 662–671. DOI: 10.1016/j.nano.2010.02.002.
11. Varvarenko SM, Figurka NV, Samarik V, Voronov A, Tarnavchik IT, Nosova NT, Dron IA, Taras RS, Voronov SA. Synthesis and surface-active properties of new polyesters — pseudopolyamino acids based on natural dibasic α-amino acids. Reports of the National Academy of Sciences of Ukraine. 2013; 5: 131–138. (in Ukrainian)
12. Vlizlo V. V. Nanobiotechnologies and Nanoproducts: achievements and prospects for research in animal husbandry and veterinary medicine. Bulletin of Agrarian Science. 2017; 5: 5–10. (in Ukrainian)